At the moment, no effective therapy is available to prevent or treat AHDS; however, several efforts have been made to find some TR-activating compounds which can cross the BBB and enter the target cells, independently from MCT8. The gene discussed is SLC16A2; the disease is Allan-Herndon-Dudley syndrome.